ArticleACS infectious diseases2024

Identification of an Optimized Clinical Development Candidate from Cilagicin, an Antibiotic That Evades Resistance by Dual Polyprenyl Phosphate Binding.

Adam Rosenzweig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.